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Editorial on the Research Topic
Cross Talk between Lymph Node Lymphatic Endothelial Cells and T-Cells during Inflammation 
and Cancer
A successful adaptive T cell immune response depends on the encounter of T cells and antigen-
presenting cells (APCs). Therefore, T cells constantly patrol the body, recirculating between the 
blood and the lymph nodes, looking for antigens drained from peripheral tissues. In the lymph 
node, lymphocytes recognize antigens upon contact with APCs, proliferate to expand few clonally 
relevant lymphocytes, differentiate into effector T cells, then exit the LNs and migrate to periph-
eral tissues to ensure immune protection. All these processes involve cellular interactions and 
migration. Lymph nodes are strategically distributed throughout the body, at the junction of the 
blood vascular and lymphatic systems. T cells spend several hours in a lymph node sampling the 
microenvironment, leaving then the lymph node via efferent lymphatic vessels (LVs). Traditionally 
considered as passive conduits, LVs appeared to be active players in the modulation of the immune 
response. The lymphatic system serves as the primary route for the metastasis of many cancers, and 
the extent of lymphangiogenesis is an important indicator in tumor progression. The promiscu-
ity of immune cells and LVs suggests that immune cells modulate this biological process during 
inflammation and cancer. Those, cross talks between LVs and the immune system can be used for 
therapeutic strategies for cancer and other pathologies.
This Research Topic brings together eight articles that provide insights into the various biological 
functions of the LECs, the ways they regulate the immune responses, and the therapeutic strategies 
that can be developed.
In their mini review, Yee et al. focused on the role of microRNAs (miRNAs) as regulators of 
LECs’ function. The authors discuss the role of miR-31 and mi-R181a that targets PROX1, the 
transcription factor controlling the upregulation of LECs’ markers. As a result, LECs’ specific genes 
expression is repressed, therefore miR-31 and mi-R181a control LECs’ differentiation and plasticity. 
Moreover, elevated levels of these miRNAs are found during inflammation suggesting a possible role 
of these miRNAs in inflammatory lymphangiogenesis. The authors suggest that they can be used as 
new therapeutic tools in inflammation and cancer.
Chemokines and their receptors are key factors in LVs’ function. In their mini review, Bonavita 
et al. discuss the role of atypical chemokine receptors (ACKRs), and in particular the role of ACKR2 
in lymphatic biology. The authors reported data showing the essential role of ACKR2 expressed 
2Elhadad and Della Bella LEC-T Cell Cross Talk
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1421
by LECs, in regulating chemokine concentration and leukocyte 
migration, promoting therefore resolution of inflammatory 
responses in infection, allergy, and cancer. Finally, they speculate 
that ACKR2 could be considered as a potential therapeutic target 
to attenuate inflammation during psoriasis and lung infection, 
or by influencing cancer cell dissemination to metastatic tissues.
Lymphatic vessels are key players in the cellular migration 
that accompanies lymphocytes patrolling during homeostasis 
and inflammation. In their review, Hunter et al. discuss in great 
details T cell migration within and between peripheral tissues and 
secondary lymphoid organs. While T cell migration within the 
lymph node occurs in a one manner where recirculating lympho-
cytes exit through efferent LVs to return to the blood circulation, 
in peripheral tissues T cells exit through afferent lymphatics to 
migrate to draining lymph node, before joining the blood circula-
tion. The authors discuss further the relevance of T cell migration 
through afferent LVs in immune surveillance and resolution of 
local inflammation, and the use of this migration process for the 
development of immunomodulatory therapies.
Number of publications reported the function of LECs as 
APCs. In their review, Humbert et al. discussed how this prop-
erty shapes the immune response. LECs express a large range of 
peripheral tissue-restricted antigens (PTAs) and present class I 
restricted PTA-derived antigens to CD8+ T cells, leading to the 
deletional tolerance of self reactive CD8+ T cells. The authors dis-
cuss further the contribution of LECs as regulators of peripheral 
T cell responses in autoimmunity and cancer.
While these papers cover the regulation of the peripheral 
immune response by LECs through different biological processes, 
LECs’ function is itself regulated by T cells during inflammation 
and cancer. We have reported that temporal inflammatory lymph 
node lymphangiogenesis is regulated by a mixed Th1/Th2/Th17 
response (1). Yeo and Angeli discuss further the cross talks 
between LECs and T cells and their implications in cancer, and 
the use of lymph node LECs as a potential therapeutic target in 
addition to immunotherapy strategies for cancer progression and 
metastasis.
Tumor vasculature plays a crucial role in shaping the tumor 
microenvironment and contributes to cancer immune evasion. 
In their review, Hendry et  al. described the mechanical and 
molecular mechanisms underlying tumor-promoting properties 
of tumor vasculature. They also explained the design of com-
bined antiangiogenic and immunotherapeutic treatments and 
summarized the drug combinations explored in preclinical and 
clinical settings. Promising results have been reported for antian-
giogenic therapy combined with immune checkpoint inhibitors 
in different types of cancer, suggesting that each treatment may 
potentiate the effect of the other. We suggest that endothelial 
colony-forming cells isolated and cultured from blood may rep-
resent a tool for studying the endothelial compartment in cancer 
patients (2, 3), and assessing the impact of combined treatments 
during patient follow-up.
Dieterich et  al. delineated the differential role played by 
lymphatic and blood vascular vessels in the tumor microenviron-
ment, highlighting a role for LVs in promoting cancer immune 
tolerance. By using two different in  vivo models, the authors 
showed that, during cancer development, tumor-associated 
LVs—but not blood vessels—upregulate the checkpoint inhibitor 
PD-L1. Notably, this effect is dependent on IFNγ production by 
tumor stromal cells. T  cell interactions with tumor-associated 
LVs, and T cell inhibition upon contact with PD-L1-expressing 
LECs, suggest that characteristics ascribed to LECs in second-
ary lymphoid organs are shared by LECs present in the tumor 
microenvironment. As reported in Lukacs-Kornek’s review 
(Lukacs-Kornek), LECs’ functions are shared by liver LECs. Our 
knowledge on liver LECs is limited to the notion that they are 
increased in chronic liver diseases and cancer. Availability of 
markers for LEC identification will clarify the contribution of 
these cells to liver disease pathogenesis.
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